Monitor for full preclinical data presentation in late 2026, which could serve as a catalyst if results are compelling. Near-term stock movement likely muted given early stage.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $1.06entry
- T+1 · 6mo ago −12.26%α −12.41% · $0.9300
- T+5 · 5mo ago −20.75%α −18.00% · $0.8400
- T+20 · 5mo ago −10.39%α −9.09% · $0.9499
- T+60 · 3mo ago −18.74%α −19.97% · $0.8614
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates greater anti-tumor activity in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer, with full data expected in late 2026. This early-stage preclinical news provides a minor catalyst but no financial impact.
Key Facts
- Pelareorep + RAS inhibitor modalities showed greater anti-tumor activity than individual approaches in a solid tumor model
- Additional studies planned in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models
- Full results from initial preclinical studies expected in fall or winter 2026
- No financial terms or material agreements disclosed
Financial Impact
No financial figures provided; preclinical stage, no immediate revenue or expense impact
Risk Factors
- Preclinical results may not translate to clinical efficacy
- No financial data or guidance provided
- Small-cap biotech volatility with low liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000037 |
| Document: 0001129928-26-000037-index-headers.html | 0001129928-26-000037 |
| Document: 0001129928-26-000037-index.html | 0001129928-26-000037 |
| Document: 0001129928-26-000037.txt | 0001129928-26-000037 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers